ZYUS.V ZYUS Life Sciences Corporation
- Market cap
- CAD 25.6M
- P/E
- -
- P/B
- 4.41x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ZYUS.V undervalued?
Graham numberThe Graham number of ZYUS Life Sciences Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ZYUS Life Sciences Corporation fundamental analysis
No fundamental analysis for ZYUS Life Sciences Corporation yet.
ZYUS Life Sciences Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ZYUS Life Sciences Corporation
ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates for medical and adult recreational. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2a clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries, arthritis, and cancer. It operates in Canada, the United States, Australia, and the European Union. ZYUS Li…
Full company profileZYUS Life Sciences Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ZYUS Life Sciences Corporation annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 207K | 298K | 351K | 481K | 405K | 406K |
| Gross Profit | 143K | -232K | 171K | 129K | 50.0K | 168K |
| Operating Income | -22.8M | -16.3M | -17.2M | -14.7M | -14.2M | -9.04M |
| EBITDA | - | -15.4M | -42.1M | -32.2M | -16.6M | -8.54M |
| Net Income | -23.5M | -24.7M | -42.6M | -33.8M | -21.7M | -12.2M |
| EPS | - | -0.35 | -0.60 | -0.45 | -0.27 | -0.15 |
| Balance Sheet | ||||||
| Total Assets | - | 64.7M | 41.6M | 14.7M | 5.08M | 4.50M |
| Total Liabilities | - | 60.0M | 18.5M | 20.0M | 26.2M | 31.5M |
| Shareholders' Equity | - | 4.74M | 23.1M | -5.34M | -21.1M | -27.0M |
| Cash & Short-term Investments | - | 212K | 3.98M | 1.90M | 233K | 202K |
| Cash Flow | ||||||
| Operating Cash Flow | -16.9M | -9.57M | -17.9M | -9.88M | -9.23M | -5.30M |
| Capital Expenditure | 4.99M | 560K | 281K | 46.0K | 11.0K | 0.00 |
| Free Cash Flow | -21.8M | -10.1M | -18.2M | -9.92M | -9.24M | -5.30M |
| Ratios | ||||||
| ROE | - | -520.1% | -184.3% | - | - | - |
| ROA | - | -38.1% | -102.3% | -230.4% | -428.1% | -271.6% |
| Net Profit Margin | -11,330.9% | -8,274.2% | -12,134.2% | -7,028.1% | -5,365.7% | -3,009.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ZYUS Life Sciences Corporation dividends
ZYUS Life Sciences Corporation has not paid dividends in the last 5 fiscal years.
Who owns ZYUS Life Sciences Corporation
- Insiders 51.94%
- Institutions 0.03%
- Public & others 48.04%
- Shares outstanding 80.1M
- Free float 39.7M
ZYUS Life Sciences Corporation company profile
- Company name
- ZYUS Life Sciences Corporation
- Ticker
- ZYUS.V
- Exchange
- TSX Venture Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- Unit 204, Saskatoon, SK, Canada, S7N 4L8
- Phone
- 888 651 9987
- Website
- zyus.com
About ZYUS Life Sciences Corporation
ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates for medical and adult recreational. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2a clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries, arthritis, and cancer. It operates in Canada, the United States, Australia, and the European Union. ZYUS Life Sciences Corporation was founded in 2018 and is headquartered in Saskatoon, Canada.
ZYUS Life Sciences Corporation management
6- Mr. Brent H. ZettlPresident, CEO, Secretary & Director · born 1962
- Mr. John L. KnowlesInterim CFO & Director
- Dr. Julie Stakiw FRCPC, M.D.Chief Medical Officer
- Mr. Scott William LivingstoneVice President of Clinical Research
- Mr. John William-Richard EagleVice President of Finance & Accounting
- Mr. Tim MillerDirector of Investor Relations & Capital Markets